News

Oppenheimer's John Stoltzfus: Biggest worry for markets is tariffs
John Stoltzfus, Oppenheimer chief investment strategist, joins CNBC's 'Squawk on the Street' to discuss how market could ...
Camtek initiated with bullish views at Oppenheimer
Oppenheimer began coverage of Israel-based Camtek (NASDAQ:CAMT) with an Outperform rating and a $100 price target. Shares of ...
James Cameron slams 'Oppenheimer' avoiding aftermath of atomic bombings on Japan as 'moral cop-out'
Filmmaker James Cameron calls "Oppenheimer" a "moral cop-out" for avoiding bombing aftermath scenes, as he develops his own ...
James Cameron Takes Issue with Christopher Nolan's Approach in “Oppenheimer”: It's a 'Moral Cop Out'
“Yeah…it’s interesting what he stayed away from,” Cameron, 70, told Deadline of Nolan, 54, when asked if he was surprised Oppenheimer won seven Oscars and grossed nearly $1 billion. “Look, I love the ...
US Weekly on MSN4d
James Cameron Says Christopher Nolan’s ‘Oppenheimer’ Was a ‘Moral Cop Out’: ‘It Dodged the Subject’
James Cameron addressed Christopher Nolan's Oppenheimer, saying that the film was a 'moral cop out' due to a lack of certain ...
Los Alamos Historical Society works to open Oppenheimer home to the public
A Los Alamos home was featured in one of the biggest summer blockbusters. Now, a group is trying to open it up for the public ...
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress
Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.
James Cameron criticises Christopher Nolan’s ‘Oppenheimer’: “A bit of a moral cop out”
James Cameron has criticised the way Christopher Nolan depicted the effects of the atomic bomb in the 2023 box office hit ...